Sildenafil 100 mg + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Female Sexual Arousal Disorder
Conditions
Female Sexual Arousal Disorder
Trial Timeline
Apr 1, 2004 → Mar 1, 2007
NCT ID
NCT00640458About Sildenafil 100 mg + Placebo
Sildenafil 100 mg + Placebo is a phase 2 stage product being developed by Pfizer for Female Sexual Arousal Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00640458. Target conditions include Female Sexual Arousal Disorder.
What happened to similar drugs?
2 of 15 similar drugs in Female Sexual Arousal Disorder were approved
Approved (2) Terminated (0) Active (13)
🔄SHR7280;Ganirelix Acetate Injection simulant + SHR7280 simulant; Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00640458 | Phase 2 | Completed |
Competing Products
20 competing products in Female Sexual Arousal Disorder